The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
JAGUAR (JACCRO PM-01): A prospective study to evaluate the clinical utility of serial comprehensive genomic profiling testing using circulating tumor DNA in patients with metastatic colorectal cancer.
 
Yu Sunakawa
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Guardant Health; Incyte; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Daiichi Sankyo; Merck; MSD K.K; Ono Pharmaceutical
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); ICON Clinical Research (Inst); IQvia (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Toshiki Masuishi
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; MSD; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takata; Takeda; Yakult Honsha
Consulting or Advisory Role - Nihonkayaku
Research Funding - Abbvie (Inst); Amgen (Inst); Boehringer Ingelheim (Inst); CMIC (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Lilly Japan (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Syneos Health (Inst)
 
Hiroyuki Takeda
Honoraria - Bristol-Myers Squibb Japan; Guardant Health
 
Sho Umegaki
No Relationships to Disclose
 
Kyongsun Pak
Employment - Pfizer (I)
 
Satoshi Yuki
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck; Miyarisan pharmaceutical; MSD K.K; Ono Pharmaceutical; Roche; Taiho Pharmaceutical; Takeda
 
Yuki Kasahara
Research Funding - Bayer
 
Tadamichi Denda
Honoraria - Ono Pharmaceutical
Speakers' Bureau - Daiichi-Sankyo; Ono Pharmaceutical
Research Funding - Amgen (Inst); Bristol Myers Squibb Foundation (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Naotoshi Sugimoto
Research Funding - Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Yoshinaga Okugawa
Honoraria - AstraZeneca; Chugai Pharma; MSD Oncology; Otsuka; Taiho Pharmaceutical; Tsumura & Co.
 
Yosuke Kumekawa
No Relationships to Disclose
 
Tomohiro Nishina
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Taito Esaki
Honoraria - Chugai Pharma; Daiichi Sankyo; Hisamitsu Pharmaceutical; Lilly; MSD; Ono Pharmaceutical; Roche Diagnostics Solutions; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - ALX Oncology (Inst); Amgen (Inst); Asahi Kasei (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Jazz Pharmaceuticals (Inst); MSD (Inst); Nihonkayaku (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Kei Muro
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); MSD (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst)
 
Wataru Ichikawa
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health; Lilly; Merck; MSD K.K; Taiho Pharmaceutical
 
Soichiro Ishihara
Speakers' Bureau - Abbvie; AI Medical Service; Amco; Asahikawa Pharma; Bayer; Covidien/Medtronic; Daiichi Sankyo; EA Pharma; Fuji Pharma; Janssen; Johnson & Johnson/MedTech; Kaken Pharmaceutical; Kyorin; Merck; Mitsubishi Tanabe Pharma; Miyarisan pharmaceutical; Mochida Pharmaceutical Co. Ltd.; Nipro Corporation; Olympus Medical Systems; Taiho Pharmaceutical; Takata; Takeda; TERUMO; Tsumura & Co.; Yakult Honsha; Zeria Pharmaceutical
Research Funding - Canon Medical System; Chugai Pharma; Covidien/Medtronic; Fuji Pharma; Fujifilm; JIMRO; Johnson & Johnson/MedTech; Kaken Pharmaceutical; Kyorin; Lilly; Miyarisan pharmaceutical; Mochida Pharmaceutical Co. Ltd.; Nippon Kayaku; Taiho Pharmaceutical; TERUMO; Zeria Pharmaceutical